Login to Your Account

Clinic Roundup

Tuesday, January 18, 2011
Advaxis Inc., of North Brunswick, N.J., received approval from the data safety monitoring board to dose remaining patients in its trial of ADXS11-001 immunotherapy in cervical dysplasia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription